Skip Navigation

Cardiovascular Research 2003 59(1):78-85; doi:10.1016/S0008-6363(03)00346-8
© 2003 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ancey, C.
Right arrow Articles by Potreau, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ancey, C.
Right arrow Articles by Potreau, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2003, European Society of Cardiology

Human cardiomyocyte hypertrophy induced in vitro by gp130 stimulation

Cecile Anceya,b, Emmanuelle Menetb,c, Pierre Corbic, Sandra Fredja, Martine Garciab, Catherine Rücker-Martind, Jocelyn Besconda, Franck Morelb, John Wijdenese, Jean-Claude Lecronb,c and Daniel Potreaua,*

aLaboratoire des Biomembranes et Signalisation Cellulaire, UMR CNRS 6558, Université de Poitiers, 40 avenue du recteur Pineau, 86022 Poitiers Cedex, France
bLaboratoire Cytokines, EA 2224, PBS, Université de Poitiers, 40 avenue du recteur Pineau, 86022 Poitiers Cedex, France
cFaculté de Médecine et de Pharmacie et Centre Hospitalier Universitaire, 86021 Poitiers, France
dLaboratoire de Physiologie Cardiovasculaire et Thymique, ESA CNRS 8078, Centre Chirurgical Marie-Lannelongue, 133 avenue de la résistance, 92350 Le Plessis Robinson, France
eDIACLONE laboratory, 1 boulevard A. Fleming, BP 1985, 25020 Besançon Cedex, France

daniel.potreau{at}univ-poitiers.fr

* Corresponding author. Tel.: +33-549-453-955; fax: +33-549-454-014

Objectives: Recent in vivo and in vitro studies in animals have demonstrated that cytokines of the IL-6 family are involved in cardiac hypertrophy and in protection of cardiomyocytes against apoptosis. The present study aims to analyse the capacity of human atrial cardiac cells (i.e., cardiomyocytes and fibroblasts) to display the gp130 receptor subunit, and to evaluate its functionality. Methods: Twenty human atrial biopsies were used for immunohistochemistry, in situ hybridisation, and western blot analysis or dissociated for isolation and primary culture of cardiac cells. Results: Fibroblasts present in tissue or maintained in primary culture clearly express gp130 whereas the signal in cardiomyocytes is weaker. Culture of cardiac cells with a gp130 agonist antibody enhances atrial natriuretic peptide (ANP), β myosin heavy chain (β-MHC) expression in cardiomyocytes, and significantly increases the cell surface area (µm2). This process could involve STAT3 (signal transducer and activator of transcription 3) phosphorylation. Conclusions: These results demonstrate that gp130 activation in human cardiac cells leads to cardiomyocyte hypertrophy. We discuss several hypotheses on the role of IL-6-type cytokines on cardiomyocyte functions.

KEYWORDS Cardiomyocytes; gp130; Human heart; Hypertrophy; Interleukin-6


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.